(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.

The three biggest winners today are Niu Technologies, Calithera Biosciences, and AXT.

The three biggest losers today are Tilray, Biolase, and Canopy Growth.

Winners today

1. Niu Technologies (NIU) – 26.11%

Niu Technologies designs, manufactures, and sells smart electric scooters in the People's Republic of China. The company offers RQi, NQi, MQi, SQi, UQi, and Gova series electric scooters and motorcycles; KQi series one kick-scooters; BQi series e-bikes; and Niu Aero Sports Bicycles. It also provides accessories and spare parts under the NIU brand name comprising scooter accessories, such as raincoats, gloves, knee pads, storage baskets and tail boxes, smart phone holders, backrests, and locks; lifestyle accessories, which includes T-shirts, coats, sweaters and hoodies, jeans, hats, bags, jewelry, notebook, badges, key chain, and mugs; and performance upgrade components that comprises of upgraded wheels, shock absorbers, brake calipers, and carbon fiber body panels. In addition, the company, through its NIU app, offers online repair request, DIY repairs, service station locator, theft reporting, smart check, and smart services, as well as NIU cover, which provides insurance services. Niu Technologies sells and services its products through city partners and franchised stores, distributors, and third-party e-commerce platforms and the company's online store. The company was incorporated in 2014 and is headquartered in Beijing, the People's Republic of China.

NASDAQ ended the session with Niu Technologies jumping 26.11% to $2.27 on Tuesday while NASDAQ jumped 0.32% to $16,306.64.

Earnings Per Share

As for profitability, Niu Technologies has a trailing twelve months EPS of $-0.32.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -13.94%.

Sales Growth

Niu Technologies’s sales growth for the current quarter is 913.7%.

Volume

Today’s last reported volume for Niu Technologies is 1767740 which is 379.34% above its average volume of 368781.

More news about Niu Technologies.

2. Calithera Biosciences (CALA) – 20.16%

Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule compounds for tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. The company offers INCB001158, an orally bioavailable arginase inhibitor of arginase that is in Phase 1/2 clinical trial for the treatment of hematology and oncology. It is developing CB-280, an oral arginase inhibitor that has completed Phase 1b clinical trial for the treatment of cystic fibrosis and chronic airway infection; and ATG-037, an orally-bioavailable small molecule inhibitor of CD73, as well as CB-668, an orally administered inhibitor of the enzyme IL4I1. The company has a license agreement with Mars, Inc. to develop and commercialize Symbioscience's portfolio of arginase inhibitors for use in human healthcare. It also has clinical trial collaboration with Pfizer to evaluate Pfizer's PARP inhibitor talazoparib and CDK4/6 inhibitor palbociclib, each in combination with telaglenasta. In addition, the company has a collaboration and license agreement with Incyte Corporation for the research, development, and commercialization of INCB001158, a small molecule arginase inhibitor for the treatment of hematology and oncology; and a license agreement with Antengene Corporation Ltd. for the development and commercialization of CB-708. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.

NASDAQ ended the session with Calithera Biosciences jumping 20.16% to $0.03 on Tuesday, after two consecutive sessions in a row of gains. NASDAQ rose 0.32% to $16,306.64, after two consecutive sessions in a row of gains, on what was a somewhat bullish trend trading session today.

Earnings Per Share

As for profitability, Calithera Biosciences has a trailing twelve months EPS of $-7.94.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -114.14%.

Moving Average

Calithera Biosciences’s value is way higher than its 50-day moving average of $0.02 and way below its 200-day moving average of $0.04.

More news about Calithera Biosciences.

3. AXT (AXTI) – 14.79%

AXT, Inc. designs, develops, manufactures, and distributes compound and single element semiconductor substrates. It produces semiconductor substrates using its proprietary vertical gradient freeze technology. The company offers indium phosphide for use in data center connectivity using light/lasers, 5G communications, fiber optic lasers and detectors, passive optical networks, silicon photonics, photonic integrated circuits, terrestrial solar cells, RF amplifier and switching, infrared light-emitting diode (LEDS) motion control, lidar for robotics and autonomous vehicles, and infrared thermal imaging. It also provides semi-insulating gallium arsenide (GaAs) substrates for use in Wi-Fi and IoT devices, transistors, direct broadcast television, power amplifiers, satellite communications, and solar cells; and semi-conducting GaAs substrates that are used in LED, screen displays, printer head lasers and LEDs, 3-D sensing using VCSELs, data center communication using VCSELs, sensors for industrial robotics/near-infrared sensors, optical couplers, solar cells, night vision goggles, lidar for robotics and autonomous vehicles, and other lasers, as well as laser machining, cutting, and drilling. In addition, the company offers germanium substrates for use in multi-junction solar cells for satellites, optical sensors and detectors, terrestrial concentrated photo voltaic cells, infrared detectors, and carrier wafer for LED. Further, it provides 6N+ and 7N+ purified gallium, boron trioxide, gallium-magnesium alloy, pyrolytic boron nitride (pBN) crucibles, and pBN insulating parts. AXT, Inc. sells its products through direct salesforce in the United States, China, and Europe, as well as through independent sales representatives and distributors in Japan, Taiwan, Korea, and internationally. The company was formerly known as American Xtal Technology, Inc. and changed its name to AXT, Inc. in July 2000. AXT, Inc. was incorporated in 1986 and is headquartered in Fremont, California.

NASDAQ ended the session with AXT jumping 14.79% to $3.57 on Tuesday while NASDAQ jumped 0.32% to $16,306.64.

Earnings Per Share

As for profitability, AXT has a trailing twelve months EPS of $-0.42.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -6.87%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

AXT’s EBITDA is -150.48.

Volume

Today’s last reported volume for AXT is 2602410 which is 5.07% above its average volume of 2476610.

Yearly Top and Bottom Value

AXT’s stock is valued at $3.57 at 17:32 EST, way below its 52-week high of $5.64 and way higher than its 52-week low of $1.89.

Sales Growth

AXT’s sales growth is 8% for the ongoing quarter and 18.3% for the next.

More news about AXT.

4. Bebe stores (BEBE) – 13.64%

bebe stores, inc. does not have significant operations. Previously, it was engaged in the design, development, and production of women's apparel and accessories. The company marketed its products under the bebe and BEBE SPORT brand names through its retail stores; bebe.com, an online store; and 39 bebe outlet stores. It also offered its products through its 82 international licensee operated stores in 22 countries. bebe stores, inc. was founded in 1976 and is headquartered in Brisbane, California.

NASDAQ ended the session with Bebe stores jumping 13.64% to $2.75 on Tuesday while NASDAQ jumped 0.32% to $16,306.64.

Earnings Per Share

As for profitability, Bebe stores has a trailing twelve months EPS of $-0.05.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -43.18%.

Yearly Top and Bottom Value

Bebe stores’s stock is valued at $2.75 at 17:32 EST, way below its 52-week high of $4.40 and way higher than its 52-week low of $2.07.

Volume

Today’s last reported volume for Bebe stores is 2500 which is 0.2% above its average volume of 2495.

More news about Bebe stores.

5. Brainstorm Cell Therapeutics (BCLI) – 12.14%

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; and Phase II clinical trial for the treatment of progressive multiple sclerosis and alzheimer's disease, as well as for other neurodegenerative diseases. The company has a partnership with Catalent for manufacturing NurOwn. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.

NASDAQ ended the session with Brainstorm Cell Therapeutics rising 12.14% to $0.73 on Tuesday, following the last session’s upward trend. NASDAQ jumped 0.32% to $16,306.64, after two sequential sessions in a row of gains, on what was a somewhat positive trend trading session today.

Earnings Per Share

As for profitability, Brainstorm Cell Therapeutics has a trailing twelve months EPS of $-0.42.

Volume

Today’s last reported volume for Brainstorm Cell Therapeutics is 862300 which is 8.6% below its average volume of 943472.

More news about Brainstorm Cell Therapeutics.

6. U.S. Gold Corp (USAU) – 9.63%

U.S. Gold Corp. engages in the exploration and development of gold and precious metals in the United States. It also explores for copper and silver deposits. The company holds 100% interests in the CK Gold project, which consists of various mining leases and other mineral rights covering approximately 1,120 acres in Laramie County, Wyoming; the Keystone project that consists of 601 unpatented lode mining claims covering approximately 20 square miles in Eureka County, Nevada; and the Challis Gold project, which consists of 77 unpatented lode mining claims covering approximately 1,710 acres in Lemhi County, Idaho. It also has earn-in agreement to acquire a 50% ownership interest in the Maggie Creek project located in Eureka County, Nevada. The company was formerly known as Dataram Corporation and changed its name to U.S. Gold Corp. in June 2017. U.S. Gold Corp. is based in Elko, Nevada.

NASDAQ ended the session with U.S. Gold Corp jumping 9.63% to $4.73 on Tuesday, after two successive sessions in a row of gains. NASDAQ jumped 0.32% to $16,306.64, after two successive sessions in a row of gains, on what was a somewhat positive trend trading session today.

Earnings Per Share

As for profitability, U.S. Gold Corp has a trailing twelve months EPS of $-0.73.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -37.96%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

U.S. Gold Corp’s EBITDA is -14.39.

Volume

Today’s last reported volume for U.S. Gold Corp is 142883 which is 245.12% above its average volume of 41400.

Moving Average

U.S. Gold Corp’s value is way above its 50-day moving average of $3.73 and way higher than its 200-day moving average of $3.76.

Yearly Top and Bottom Value

U.S. Gold Corp’s stock is valued at $4.73 at 17:32 EST, way below its 52-week high of $7.48 and way above its 52-week low of $2.92.

More news about U.S. Gold Corp.

7. Accelerate Diagnostics (AXDX) – 9.51%

Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona.

NASDAQ ended the session with Accelerate Diagnostics jumping 9.51% to $0.92 on Tuesday, following the last session’s upward trend. NASDAQ jumped 0.32% to $16,306.64, after two consecutive sessions in a row of gains, on what was a somewhat up trend exchanging session today.

Earnings Per Share

As for profitability, Accelerate Diagnostics has a trailing twelve months EPS of $-5.52.

Sales Growth

Accelerate Diagnostics’s sales growth is 6.7% for the ongoing quarter and 2.7% for the next.

Revenue Growth

Year-on-year quarterly revenue growth grew by 11.5%, now sitting on 12M for the twelve trailing months.

Yearly Top and Bottom Value

Accelerate Diagnostics’s stock is valued at $0.92 at 17:32 EST, way under its 52-week high of $11.90 and way higher than its 52-week low of $0.83.

Growth Estimates Quarters

The company’s growth estimates for the current quarter and the next is 57.6% and 76.3%, respectively.

More news about Accelerate Diagnostics.

8. Nio (NIO) – 7.79%

NIO Inc. designs, develops, manufactures, and sells smart electric vehicles in China. It offers five and six-seater electric SUVs, as well as smart electric sedans. The company also offers power solutions, including Power Home, a home charging solution; Power Swap, a battery swapping service; Power Charger and Destination Charger; Power Mobile, a mobile charging service through charging vans; Power Map, an application that provides access to a network of public chargers and their real-time information; and One Click for Power valet service. In addition, it provides repair, maintenance, and bodywork services through its NIO service centers and authorized third-party service centers; statutory and third-party liability insurance, and vehicle damage insurance through third-party insurers; repair and routine maintenance; courtesy vehicle services; roadside assistance; data packages; and auto financing and financial leasing services. Further, the company involved in the provision of energy and service packages to its users; design and technology development activities; manufacture of e-powertrains, battery packs, and components; and sales and after sales management activities. Additionally, it offers NIO Certified, a used vehicle inspection, evaluation, acquisition, and sales service. The company was formerly known as NextEV Inc. and changed its name to NIO Inc. in July 2017. NIO Inc. was incorporated in 2014 and is headquartered in Shanghai, China.

NYSE ended the session with Nio jumping 7.79% to $4.71 on Tuesday, after two consecutive sessions in a row of losses. NYSE jumped 0.09% to $18,171.20, after two consecutive sessions in a row of gains, on what was a somewhat bullish trend trading session today.

Earnings Per Share

As for profitability, Nio has a trailing twelve months EPS of $-1.73.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -73.45%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 6.5%, now sitting on 55.62B for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Nio’s stock is considered to be overbought (>=80).

Volatility

Nio’s last week, last month’s, and last quarter’s current intraday variation average was a negative 1.13%, a negative 1.61%, and a positive 3.20%.

Nio’s highest amplitude of average volatility was 1.28% (last week), 2.70% (last month), and 3.20% (last quarter).

More news about Nio.

9. Amkor Technology (AMKR) – 7.69%

Amkor Technology, Inc. provides outsourced semiconductor packaging and test services in the United States, Japan, Europe, the Middle East, Africa, and the Asia Pacific. It offers turnkey packaging and test services, including semiconductor wafer bump, wafer probe, wafer back-grind, package design, packaging, system-level and final test, and drop shipment services; flip chip scale package products for smartphones, tablets, and other mobile consumer electronic devices; flip chip stacked chip scale packages that are used to stack memory digital baseband, and as applications processors in mobile devices; flip-chip ball grid array packages for various networking, storage, computing, automotive, and consumer applications; and memory products for system memory or platform data storage. The company also provides wafer-level CSP packages for power management, transceivers, sensors, wireless charging, codecs, radar, and specialty silicon; wafer-level fan-out packages used in power management, transceivers, radar, and specialty silicon; silicon wafer integrated fan-out technology that replaces a laminate substrate with a thinner structure; leadframe packages for electronic devices and mixed-signal applications; and substrate-based wirebond packages used to connect a die to a substrate. In addition, it offers micro-electro-mechanical systems packages that are miniaturized mechanical and electromechanical devices; and advanced system-in-package modules used in radio frequency and front end modules, basebands, connectivity, fingerprint sensors, display and touch screen drivers, sensors and MEMS, and NAND memory and solid-state drives. Further, the company provides wafer, package, and system level test services, as well as burn-in test and test development services. It serves integrated device manufacturers, fabless semiconductor companies, original equipment manufacturers, and contract foundries. The company was founded in 1968 and is headquartered in Tempe, Arizona.

NASDAQ ended the session with Amkor Technology jumping 7.69% to $33.75 on Tuesday while NASDAQ rose 0.32% to $16,306.64.

Earnings Per Share

As for profitability, Amkor Technology has a trailing twelve months EPS of $1.46.

PE Ratio

Amkor Technology has a trailing twelve months price to earnings ratio of 23.12. Meaning, the purchaser of the share is investing $23.12 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.41%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Amkor Technology’s EBITDA is 1.28.

Dividend Yield

As maintained by Morningstar, Inc., the next dividend payment is on Mar 11, 2024, the estimated forward annual dividend rate is 0.32 and the estimated forward annual dividend yield is 0.9%.

Revenue Growth

Year-on-year quarterly revenue growth declined by 8.1%, now sitting on 6.5B for the twelve trailing months.

Growth Estimates Quarters

The company’s growth estimates for the present quarter and the next is a negative 38.9% and a negative 34.6%, respectively.

More news about Amkor Technology.

10. Bilibili (BILI) – 7.67%

Bilibili Inc. provides online entertainment services for the young generations in the People's Republic of China. It offers a range of digital content, including professional user generated videos, mobile games, and value-added services, such as live broadcasting, occupationally generated videos, audio drama on Maoer, and comics on Bilibili Comic. The company also provides advertising services; and IP derivatives and other services. In addition, it engages in the business and technology development activities; e-commerce business; and video, comics, and game distribution activities. Bilibili Inc. was founded in 2009 and is headquartered in Shanghai, the People's Republic of China.

NASDAQ ended the session with Bilibili rising 7.67% to $11.93 on Tuesday, following the last session’s upward trend. NASDAQ rose 0.32% to $16,306.64, after two successive sessions in a row of gains, on what was a somewhat bullish trend trading session today.

Earnings Per Share

As for profitability, Bilibili has a trailing twelve months EPS of $-1.62.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -32.46%.

Growth Estimates Quarters

The company’s growth estimates for the current quarter and the next is 51.4% and 56.2%, respectively.

Yearly Top and Bottom Value

Bilibili’s stock is valued at $11.93 at 17:32 EST, way under its 52-week high of $25.58 and way higher than its 52-week low of $8.80.

Sales Growth

Bilibili’s sales growth is 11.5% for the current quarter and 17.1% for the next.

More news about Bilibili.

Losers Today

1. Tilray (TLRY) – -20.66%

Tilray Brands, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis products in Canada, the United States, Europe, Australia, New Zealand, Latin America, and internationally. The company operates through four segments: Cannabis Business, Distribution Business, Beverage Alcohol Business, and Wellness Business. It also offers medical and adult-use cannabis products; purchases and resells pharmaceutical and wellness products; and produces, markets, sells, and distributes beverage alcohol products, and hemp-based food and other wellness products. In addition, the company offers its products under the Tilray, Aphria, Broken Coast, Symbios, B!NGO, The Batch, Dubon, Good Supply, Solei, Chowie Wowie, Canaca, RIFF, SweetWater, Breckenridge Distillery, Alpine Beer Company, and Green Flash brands. It sells its products to retailers, wholesalers, patients, physicians, hospitals, pharmacies, researchers, and governments, as well as direct to consumers. The company was formerly known as Tilray, Inc. and changed its name to Tilray Brands, Inc. in January 2022. Tilray Brands, Inc. is headquartered in Leamington, Canada.

NASDAQ ended the session with Tilray falling 20.66% to $2.06 on Tuesday, after three sequential sessions in a row of losses. NASDAQ jumped 0.32% to $16,306.64, after two sequential sessions in a row of gains, on what was a somewhat positive trend exchanging session today.

Earnings Per Share

As for profitability, Tilray has a trailing twelve months EPS of $-2.28.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -36%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Tilray’s stock is considered to be overbought (>=80).

Earnings Before Interest, Taxes, Depreciation, and Amortization

Tilray’s EBITDA is -151.76.

More news about Tilray.

2. Biolase (BIOL) – -13.23%

BIOLASE, Inc., together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, such as cosmetic, restorative, and complex surgical applications. The company offers Waterlase all-tissue dental laser systems for cutting soft and hard tissues; diode soft-tissue laser systems for soft tissue, pain therapy, teeth whitening, and cosmetic procedures; and Epic Hygiene laser to manage non-surgical periodontitis and enhance clinical production. It also manufactures and sells consumable products and accessories for its laser systems, as well as markets flexible fibers and hand pieces, and teeth whitening gel kits. The company sells its products through its field sales force and distributor network. The company was formerly known as BIOLASE Technology, Inc. and changed its name to BIOLASE, Inc. in 2012. BIOLASE, Inc. was founded in 1984 and is headquartered in Foothill Ranch, California.

NASDAQ ended the session with Biolase sliding 13.23% to $0.15 on Tuesday, after five successive sessions in a row of losses. NASDAQ jumped 0.32% to $16,306.64, after two consecutive sessions in a row of gains, on what was a somewhat bullish trend exchanging session today.

Earnings Per Share

As for profitability, Biolase has a trailing twelve months EPS of $-29.44.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -602.83%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Biolase’s EBITDA is -4.31.

Revenue Growth

Year-on-year quarterly revenue growth declined by 4%, now sitting on 49.16M for the twelve trailing months.

Yearly Top and Bottom Value

Biolase’s stock is valued at $0.15 at 17:32 EST, way under its 52-week high of $47.00 and way above its 52-week low of $0.13.

More news about Biolase.

3. Canopy Growth (CGC) – -9.58%

Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in Canada, the United States, and Germany. It operates through two segments, Global Cannabis and Other Consumer Products. The company's products include dried cannabis flower, extracts and concentrates, beverages, gummies, and vapes. It offers its products under the Tweed, 7ACRES, 7ACRES Craft Collective, DOJA, Ace Valley, Quatreau, Deep Space, First + Free, Surity Pro, Spectrum Therapeutics, Vert, Tokyo Smoke, Twd, Martha Stewart CBD, DNA Genetics, BioSteel, Storz & Bickel, This Works, HiWay, Simple Stash, Whisl, and Truverra brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation was incorporated in 2009 and is headquartered in Smiths Falls, Canada.

NASDAQ ended the session with Canopy Growth falling 9.58% to $9.16 on Tuesday, after two successive sessions in a row of losses. NASDAQ jumped 0.32% to $16,306.64, after two sequential sessions in a row of gains, on what was a somewhat up trend exchanging session today.

Earnings Per Share

As for profitability, Canopy Growth has a trailing twelve months EPS of $-15.67.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -121.56%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Canopy Growth’s EBITDA is 1.8.

More news about Canopy Growth.

4. Carver Bancorp (CARV) – -9.43%

Carver Bancorp, Inc. operates as the holding company for Carver Federal Savings Bank that provides consumer and commercial banking services for consumers, businesses, non-profit organizations, and governmental and quasi-governmental agencies primarily in New York. It accepts various deposit products, including demand, savings, and time deposits; passbook and statement accounts, and certificates of deposit; and individual retirement accounts. The company also provides lending products, such as one-to-four family residential, multifamily real estate, and commercial real estate lending; and construction, business and small business administration, and consumer and other loans. In addition, it offers other consumer and commercial banking products and services, including debit cards, online account opening and banking, online bill pay, and telephone banking, as well as check cashing, wire transfer, bill payment, reloadable prepaid card, and money order services. The company operates through one administrative office, seven branches, and four ATMs. Carver Bancorp, Inc. was founded in 1948 and is headquartered in New York, New York.

NASDAQ ended the session with Carver Bancorp sliding 9.43% to $1.44 on Tuesday while NASDAQ rose 0.32% to $16,306.64.

Earnings Per Share

As for profitability, Carver Bancorp has a trailing twelve months EPS of $-0.98.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -10.22%.

More news about Carver Bancorp.

5. Aurora Cannabis (ACB) – -9.34%

Aurora Cannabis Inc., together with its subsidiaries, produces, distributes, and sells cannabis and cannabis-derivative products in Canada and internationally. It operates through three segments: Canadian Cannabis, European Cannabis, and Plant Propagation. The company produces, distributes, and sells medical and consumer cannabis products in Canada. It is also involved in the distribution of wholesale medical cannabis in the European Union (EU); distribution of wholesale medical cannabis in various international markets, including Australia, the Caribbean, South America, and Israel; supply of propagated vegetables and ornamental plants in North America; and distribution and sale of hemp-derived cannabidiol (CBD) products. In addition, the company cultivates and sells dried cannabis, cannabis oils, capsules, edible cannabis, cannabis extracts, and soft gels, which are ingested in various ways, including smoking, vaporizing, and consumption in the form of oil, capsules, edibles, and extracts; and provides dried flowers, vapes, dried milled strains, strain-specific extracts, strain specific cannabis oils, and concentrates. Further, it offers recreational cannabis products, such as flowers, vapes, ingestibles, concentrates, extracts, and CBD products; and patient counseling and outreach services. The company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, as well as CBD brands, Reliva and KG7; and medical cannabis brands include MedReleaf, CanniMed, Aurora, Whistler Medical Marijuana Co, Pedanios, Bidiol, and CraftPlant. Aurora Cannabis Inc. is headquartered in Edmonton, Canada.

NYSE ended the session with Aurora Cannabis sliding 9.34% to $6.36 on Tuesday while NYSE rose 0.09% to $18,171.20.

Earnings Per Share

As for profitability, Aurora Cannabis has a trailing twelve months EPS of $-58.28.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -102.67%.

More news about Aurora Cannabis.

6. Bio-Path Holdings (BPTH) – -8.47%

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 that is in preclinical stage for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and prexigebersen-A for various solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.

NASDAQ ended the session with Bio-Path Holdings dropping 8.47% to $3.89 on Tuesday, after three sequential sessions in a row of losses. NASDAQ rose 0.32% to $16,306.64, after two sequential sessions in a row of gains, on what was a somewhat bullish trend trading session today.

Earnings Per Share

As for profitability, Bio-Path Holdings has a trailing twelve months EPS of $-33.63.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -220.02%.

Yearly Top and Bottom Value

Bio-Path Holdings’s stock is valued at $3.89 at 17:32 EST, way below its 52-week high of $44.80 and way above its 52-week low of $3.51.

More news about Bio-Path Holdings.

7. SNDL Inc. (SNDL) – -8.05%

SNDL Inc. engages in the production, distribution, and sale of cannabis products in Canada. The company operates through Liquor Retail, Cannabis Retail, Cannabis Operations, and Investments segments. It engages in the cultivation, distribution, and sale of cannabis for the adult-use and medical markets; sells wines, beers, and spirits through wholly owned liquor stores; and private sale of recreational cannabis through wholly owned and franchised retail cannabis stores. In addition, the company produces and distributes inhalable products, such as flower, pre-rolls, and vapes. It offers its products under the Top Leaf, Sundial Cannabis, Palmetto, and Grasslands brands. The company was formerly known as Sundial Growers Inc. and changed its name to SNDL Inc. in July 2022. SNDL Inc. was incorporated in 2006 and is headquartered in Calgary, Canada.

NASDAQ ended the session with SNDL Inc. sliding 8.05% to $2.09 on Tuesday while NASDAQ rose 0.32% to $16,306.64.

Earnings Per Share

As for profitability, SNDL Inc. has a trailing twelve months EPS of $-0.48.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -17.6%.

Yearly Top and Bottom Value

SNDL Inc.’s stock is valued at $2.09 at 17:32 EST, way under its 52-week high of $2.36 and way higher than its 52-week low of $1.25.

Earnings Before Interest, Taxes, Depreciation, and Amortization

SNDL Inc.’s EBITDA is -130.36.

Sales Growth

SNDL Inc.’s sales growth for the current quarter is 971.6%.

More news about SNDL Inc..

8. FibroGen (FGEN) – -7.67%

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

NASDAQ ended the session with FibroGen sliding 7.67% to $1.51 on Tuesday while NASDAQ rose 0.32% to $16,306.64.

Earnings Per Share

As for profitability, FibroGen has a trailing twelve months EPS of $-2.92.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, FibroGen’s stock is considered to be oversold (<=20).

Sales Growth

FibroGen’s sales growth for the current quarter is 14.5%.

Volatility

FibroGen’s last week, last month’s, and last quarter’s current intraday variation average was a negative 12.31%, a negative 1.02%, and a positive 8.44%.

FibroGen’s highest amplitude of average volatility was 18.98% (last week), 7.81% (last month), and 8.44% (last quarter).

More news about FibroGen.

9. Bellicum Pharmaceuticals (BLCM) – -6.68%

Bellicum Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen; and BPX-603, a dual-switch GoCAR-T product candidate that is in Phase 1/2 clinical trials to treat solid tumors that express the human epidermal growth factor receptor 2 antigens. Its clinical product candidates also include Rivo-cel, an allogeneic T cell product candidate intended to enhance outcomes in the treatment of leukemias, lymphomas, and inherited blood disorders. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in Houston, Texas.

NASDAQ ended the session with Bellicum Pharmaceuticals sliding 6.68% to $0.07 on Tuesday while NASDAQ jumped 0.32% to $16,306.64.

Earnings Per Share

As for profitability, Bellicum Pharmaceuticals has a trailing twelve months EPS of $-0.67.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -148.5%.

Moving Average

Bellicum Pharmaceuticals’s worth is way below its 50-day moving average of $0.11 and way below its 200-day moving average of $0.26.

Yearly Top and Bottom Value

Bellicum Pharmaceuticals’s stock is valued at $0.07 at 17:32 EST, way under its 52-week high of $1.31 and way higher than its 52-week low of $0.06.

More news about Bellicum Pharmaceuticals.

10. Atossa Therapeutics (ATOS) – -6.42%

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201, an inhalation therapy to improve lung function in severely ill and hospitalized COVID-19 patients; AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with COVID-19; and immunotherapy/chimeric antigen receptor therapy programs for the treatment of breast cancer. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.

NASDAQ ended the session with Atossa Therapeutics falling 6.42% to $1.75 on Tuesday, after two consecutive sessions in a row of losses. NASDAQ jumped 0.32% to $16,306.64, after two sequential sessions in a row of gains, on what was a somewhat up trend exchanging session today.

Earnings Per Share

As for profitability, Atossa Therapeutics has a trailing twelve months EPS of $-0.24.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -26.86%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Atossa Therapeutics’s stock is considered to be overbought (>=80).

More news about Atossa Therapeutics.

Stay up to date with our winners and losers daily report